Kenneth C. Anderson

Boston University — United States

Medicine · Health Sciences

199h-index166.6kcitations3.1kworks2.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(1928), Protein Degradation and Inhibitors(883), Peptidase Inhibition and Analysis(555), Ubiquitin and proteasome pathways(356), Chronic Lymphocytic Leukemia Research(240)

Publications3.1k total

RVd and CyBorD therapies remodel B-cell maturation signaling and alter immune and clonal architecture in multiple myeloma
Cancer Biology & Therapy·2025Open Access
Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma
Journal of Clinical Oncology·2025· 1 cited
Data from Cancer in 2025
2025Open Access
Cancer in 2025
Cancer Discovery·2025· 1 cited
Group Authors List 1 from Cancer in 2025
2025Open Access
Supplementary Figure S2 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
2025Open Access
Supplemental Table S1 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
2025Open Access
Supplementary Data S3 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
2025Open Access
Supplementary Data S1 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
2025Open Access
Supplementary Figure S3 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
2025Open Access
Supplementary Figure S4 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
2025Open Access
Supplementary Figure S1 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
2025Open Access
Supplementary Data S2 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
2025Open Access
Supplementary Figure S5 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
2025Open Access
Supplementary Materials S1 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
2025Open Access
The Global State of Blood Cancers: An Ongoing Challenge
Blood Cancer Discovery·2025
Spatial proteomics of the bone marrow reveals distinct Tumor–Immune niches in smoldering and relapsed myeloma and their remodeling in response to bispecific antibody and CAR-T therapy
Blood·2025Open Access
Single-cell immune profiling reveals enhanced immune fitness of endogenous and engineered T cells in patients with high-risk smoldering myeloma compared to Relapsed/Refractory myeloma following bispecific antibodies or CAR-T cell therapies.
Blood·2025Open Access
The B2M–LILRB1 axis as a novel myeloid immune checkpoint and therapeutic target in multiple myeloma
Blood·2025
The impact of Duffy genotype on progression-free survival (PFS) with lenalidomide, Bortezomib, and dexamethasone (RVd) alone or RVd plus autologous stem cell transplantation (ASCT) and continuous R maintenance in patients (pts) with newly diagnosed multiple myeloma (NDMM): Updated subgroup analysis of the phase 3 DETERMINATION trial
Blood·2025Open Access
page 1 of 154Next →

Frequent Co-authors

Paul G. Richardson(35), S. Vincent Rajkumar(17), Jesús F. San Miguel(16), Teru Hideshima(16), Meletios Α. Dimopoulos(13), Sagar Lonial(13), Antonio Palumbo(12), Dharminder Chauhan(11), Sundar Jagannath(10), Brian G.M. Durie(10), Nikhil C. Munshi(10), Pieter Sonneveld(10), Constantine S. Mitsiades(10), Philippe Moreau(9), Robert Z. Orlowski(9), Michel Attal(9), Joan Bladé(8), María‐Victoria Mateos(8), Robert A. Kyle(8), Michèle Cavo(7)